4.52
前日終値:
$4.33
開ける:
$4.35
24時間の取引高:
1.07M
Relative Volume:
1.05
時価総額:
$87.42M
収益:
$1.54M
当期純損益:
$-84.53M
株価収益率:
-0.7774
EPS:
-5.8145
ネットキャッシュフロー:
$-73.65M
1週間 パフォーマンス:
-15.99%
1か月 パフォーマンス:
-37.74%
6か月 パフォーマンス:
-55.42%
1年 パフォーマンス:
-76.27%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
4.52 | 87.42M | 1.54M | -84.53M | -73.65M | -5.8145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-29 | 開始されました | Guggenheim | Buy |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38 - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP) - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
EBITDA of Corbus Pharmaceuticals Holdings Inc – HAN:3371 - TradingView
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - finance.yahoo.com
About 14,000 U.S. patients may qualify yearly for another throat cancer treatment. Corbus doses its first trial patient. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - Kalkine Media
(CRBP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings (Nasdaq:CRBP)Stock Analysis - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP - Finviz
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss TherapySlideshow (NASDAQ:CRBP) 2026-09-17 - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data - finance.yahoo.com
Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Corbus Pharmaceuticals to Host Sept. 14 Webcast on Topline CANYON-1 Phase 1b Data for CRB-913 in Obesity - Quiver Quantitative
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada
Corbus Pharmaceuticals to Host Conference Call to Discuss - GlobeNewswire
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
Corbus Pharmaceuticals Holdings Inc (CRBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Saxena Nishant C | Chief Business Officer |
Aug 11 '26 |
Buy |
9.63 |
2,600 |
25,036 |
77,900 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
17,000 |
171,396 |
0 |
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
12,000 |
120,971 |
0 |
| Smethurst Dominic | Officer |
Jul 27 '26 |
Proposed Sale |
9.20 |
23,025 |
211,818 |
0 |
| Kung Winston | Director |
Jun 10 '26 |
Sale |
7.91 |
2,026 |
16,033 |
12,140 |
| Altmeyer Anne | Director |
Jun 10 '26 |
Sale |
7.91 |
2,412 |
19,088 |
7,579 |
| Jenkins John Kenneth | Director |
Jun 10 '26 |
Sale |
7.91 |
4,800 |
37,986 |
3,833 |
| Saxena Nishant C | Chief Business Officer |
Jun 03 '26 |
Buy |
7.58 |
9,000 |
68,220 |
75,300 |
大文字化:
|
ボリューム (24 時間):